CN102596192A - 二甲双胍在癌症治疗和预防中的用途 - Google Patents

二甲双胍在癌症治疗和预防中的用途 Download PDF

Info

Publication number
CN102596192A
CN102596192A CN2010800480600A CN201080048060A CN102596192A CN 102596192 A CN102596192 A CN 102596192A CN 2010800480600 A CN2010800480600 A CN 2010800480600A CN 201080048060 A CN201080048060 A CN 201080048060A CN 102596192 A CN102596192 A CN 102596192A
Authority
CN
China
Prior art keywords
metformin
cancer
cells
tumor
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800480600A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·施特尔
希瑟·赫希
季米特里斯·伊利奥普洛斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN102596192A publication Critical patent/CN102596192A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800480600A 2009-08-25 2010-08-25 二甲双胍在癌症治疗和预防中的用途 Pending CN102596192A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
US61/236,778 2009-08-25
PCT/US2010/046616 WO2011031474A2 (en) 2009-08-25 2010-08-25 Use of metformin in cancer treatment and prevention

Publications (1)

Publication Number Publication Date
CN102596192A true CN102596192A (zh) 2012-07-18

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800480600A Pending CN102596192A (zh) 2009-08-25 2010-08-25 二甲双胍在癌症治疗和预防中的用途

Country Status (14)

Country Link
US (1) US20120220664A1 (enExample)
EP (1) EP2470170A4 (enExample)
JP (1) JP2013503171A (enExample)
KR (1) KR20120080579A (enExample)
CN (1) CN102596192A (enExample)
AU (1) AU2010292599A1 (enExample)
BR (1) BR112012004281A2 (enExample)
CA (1) CA2772120A1 (enExample)
IL (1) IL218287A0 (enExample)
IN (1) IN2012DN01964A (enExample)
MX (1) MX2012002337A (enExample)
SG (1) SG178556A1 (enExample)
WO (1) WO2011031474A2 (enExample)
ZA (1) ZA201201434B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
CN107148274A (zh) * 2014-08-19 2017-09-08 国立大学法人冈山大学 增强免疫细胞功能的方法和评估免疫细胞多功能性的方法
WO2025157212A1 (zh) * 2024-01-23 2025-07-31 成都夸常奥普医疗科技有限公司 包含n，n-二甲基亚双胍的制剂、和包含n,n-二甲基亚双胍与药物的药物组合、组合物、试剂盒及其用途和制备方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040310A1 (en) * 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
BR112013014076A2 (pt) * 2010-12-06 2016-11-22 Cure Cancer Worldwide Corp métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
US9532984B2 (en) * 2011-06-10 2017-01-03 The Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
BR112015024537B1 (pt) * 2013-04-12 2022-09-06 Ned Biosystems, Inc Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
JP6440212B2 (ja) 2013-05-24 2018-12-19 株式会社加齢・栄養研究所 メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
WO2017142485A1 (en) * 2016-02-16 2017-08-24 Agency For Science, Technology And Research Cancer epigenetic profiling
CA3059210C (en) * 2016-05-19 2022-07-19 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN117338938A (zh) * 2019-02-28 2024-01-05 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2024233616A1 (en) * 2023-05-11 2024-11-14 Wainer Irving W Method for treating cancer
WO2025085311A1 (en) * 2023-10-16 2025-04-24 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of kmt2d-deficient cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799263A4 (en) * 2004-09-15 2009-07-29 Harvard College REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALTER H. GOTLIEB ET AL: "In vitro metformin anti-neoplastic activity in epithelial ovarian cancer", 《GYNECOLOGIC ONCOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148274A (zh) * 2014-08-19 2017-09-08 国立大学法人冈山大学 增强免疫细胞功能的方法和评估免疫细胞多功能性的方法
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
WO2025157212A1 (zh) * 2024-01-23 2025-07-31 成都夸常奥普医疗科技有限公司 包含n，n-二甲基亚双胍的制剂、和包含n,n-二甲基亚双胍与药物的药物组合、组合物、试剂盒及其用途和制备方法

Also Published As

Publication number Publication date
KR20120080579A (ko) 2012-07-17
SG178556A1 (en) 2012-03-29
US20120220664A1 (en) 2012-08-30
IL218287A0 (en) 2012-04-30
WO2011031474A2 (en) 2011-03-17
JP2013503171A (ja) 2013-01-31
CA2772120A1 (en) 2011-03-17
IN2012DN01964A (enExample) 2015-08-21
BR112012004281A2 (pt) 2016-03-08
EP2470170A4 (en) 2013-01-02
AU2010292599A1 (en) 2012-03-15
EP2470170A2 (en) 2012-07-04
MX2012002337A (es) 2012-06-25
WO2011031474A3 (en) 2011-06-16
ZA201201434B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
CN102596192A (zh) 二甲双胍在癌症治疗和预防中的用途
Aranda et al. Nitric oxide and cancer: the emerging role of S-nitrosylation
US11357850B2 (en) Methods for treating breast cancer using INOS-inhibitory compositions
Perri et al. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options
JP6621501B2 (ja) 新規癌治療法としてのアリール炭化水素受容体（ＡｈＲ）改変物質
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
KR20190084291A (ko) 암 치료를 위한 제약 조성물 및 방법
WO2020230701A1 (ja) 抗腫瘍剤及び配合剤
KR20190089191A (ko) 티로신 유도체 및 이들을 포함하는 조성물
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
US11583509B2 (en) Compound for treating cancer and diabetes
HK1173378A (en) Use of metformin in cancer treatment and prevention
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
O’Connor et al. New drugs for the treatment of advanced-stage diffuse large cell lymphomas
JP2014513698A (ja) がん治療保護のためのヒ素の使用
HK40061465A (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
Seo et al. Comparison between therapeutic efficacies of histone deacetylase inhibitors and established drug regimens against breast cancer cells using the histoculture drug response assay

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1173378

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120718